Current position:News > News > Insights
HER2: FDA Approves Application for Phase I Clinical Trial of Paragon HER2 ADC for Solid Tumours
吉满生物
2024-11-08
On 8 Nov., SystImmune, Inc. received notification from the US FDA that its Phase I clinical trial application for BL-M17D1 (ADC) for the treatment of patients with advanced solid tumours has been approved by the FDA.

A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumorsimage.png

This study is an open, multicenter, dose-escalation and expansion-enrollment nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M17D1 in patients with locally advanced or metastatic HER2 positive/negative breast cancer and other solid tumors.


At present, including the new FDA licence for BL-M17D1, the Company has a total of six projects that have been licensed by the FDA to conduct clinical research, and the other five are: BL-B01D1, BL-M07D1, SI-B001, BL-M05D1, BL-M11D1 clinical trials in the United States.

Learn more about our HER2 catalog.

Latest news
Insights
2025-12-24
IL-5: a key regulator of eosinophilic inflammation
Interleukin-5 (IL-5) is a key driver of eosinophilic inflammation, underlying conditions such as severe asthma, chronic rhinosinusitis with nasal polyps, and other allergic or inflammatory diseases. Recent advances in IL-5–targeted therapies, including GSK’s next-generation ultra-long-acting antibody Depemokimab (Exdensur), are transforming the treatment landscape. With extended dosing intervals and proven efficacy, these therapies offer new hope for improved patient outcomes and quality of life.
Insights
2025-12-24
IL-5: a key regulator of eosinophilic inflammation
Interleukin-5 (IL-5) is a key driver of eosinophilic inflammation, underlying conditions such as severe asthma, chronic rhinosinusitis with nasal polyps, and other allergic or inflammatory diseases. Recent advances in IL-5–targeted therapies, including GSK’s next-generation ultra-long-acting antibody Depemokimab (Exdensur), are transforming the treatment landscape. With extended dosing intervals and proven efficacy, these therapies offer new hope for improved patient outcomes and quality of life.
Insights
2025-12-17
Could GDF15 Become the Next Super Target After PD-1 and GLP-1?
A recent Nature Aging study reveals that senescent tumor-adjacent epithelial cells secrete GDF15, driving colorectal cancer progression via a metabolic–epigenetic feedback loop. This expands GDF15’s role beyond tumor cells to its influence on the surrounding microenvironment.

Emerging as a hub connecting tumor growth, immune evasion, and systemic metabolism, GDF15 is a promising target across oncology, cancer cachexia, obesity, and metabolic diseases. Monoclonal antibodies like Ponsegromab and Visugromab are showing encouraging results in early clinical trials.
Current position:News > News > Insights
classify
HER2: FDA Approves Application for Phase I Clinical Trial of Paragon HER2 ADC for Solid Tumours
吉满生物
2024-11-08
On 8 Nov., SystImmune, Inc. received notification from the US FDA that its Phase I clinical trial application for BL-M17D1 (ADC) for the treatment of patients with advanced solid tumours has been approved by the FDA.

A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumorsimage.png

This study is an open, multicenter, dose-escalation and expansion-enrollment nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M17D1 in patients with locally advanced or metastatic HER2 positive/negative breast cancer and other solid tumors.


At present, including the new FDA licence for BL-M17D1, the Company has a total of six projects that have been licensed by the FDA to conduct clinical research, and the other five are: BL-B01D1, BL-M07D1, SI-B001, BL-M05D1, BL-M11D1 clinical trials in the United States.

Learn more about our HER2 catalog.

Message consultation
reset
submit
Message
Message consultation
reset
submit